Gains in its proton therapy segment offset a decline in dosimetry products to grow revenues for radiopharmaceutical developer Ion Beam Applications (IBA) in the third quarter (end-September 30).
Consolidated revenues advanced 9% to 292.8 million euros ($392.5 million U.S.) compared with the third quarter of 2010. The company's net debt amounted to 22.6 million euros ($30.3 million U.S.), which is greater than the June 30, 2011, amount.
IBA said that it expects fourth-quarter revenues to increase based on booked orders in 2010 and 2011.
